The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.

摘要: We compared findings from recent studies modelling the cost-effectiveness of screening for cervical cancer using human papillomavirus (HPV) testing and alternative strategies. Data were standardized to facilitate comparison costs per life year or QALY gained in six studies. Absolute changes costs, years QALYs each strategy normalized a with no screening. Costs US$ 2000 values. Most models assume starts at age 18 20 years. Assumed prevalence HPV ranges 10% those aged 18 years 20% 20–25 years drops substantially after 30. All except one model sensitivity LSIL 83% higher. Two distinguish increasing specificity older groups (up 95% women 55 years older). include consultation as well treatment but follow-up diagnosis vary considerably. also patient time costs. Despite these differences all strategies involving have cost quality-adjusted life-year (QALY) ratios range $12,400–$16,600. more widely, highest being $19,246 (annual liquid cytology HPV). However, excluding cytology, including are under $14,000 (simultaneous conventional every two years). The alone triennially is lower than Pap smear biennially. generally (given reported assumptions settings). Even inclusion $16,600 QALY. Adoption ACOG guidelines option 30 years therefore appears be cost-effective.